TDMS Study 88133-06 Pathology Tables
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Date: 07/12/02
Route: SKIN APPLICATION Time: 08:48:56
Final#2
Facility: Battelle Columbus Laboratory
Chemical CAS #: 15625-89-5
Lock Date: 06/16/99
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include 002 0 MG/KG
Include 001 0 MG/KG
Include 004 0.75 MG/KG
Include 003 0.75 MG/KG
Include 006 1.5 MG/KG
Include 005 1.5 MG/KG
Include 008 3 MG/KG
Include 007 3 MG/KG
Include 010 6 MG/KG
Include 009 6 MG/KG
Include 012 12 MG/KG
Include 011 12 MG/KG
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Date: 07/12/02
Route: SKIN APPLICATION Time: 08:48:56
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 15 15 15 15 15 15
Early Deaths
Natural Death 1 2 1 1 3
Moribund Sacrifice 1
Survivors
Terminal Sacrifice 15 14 12 14 14 12
Animals Examined Microscopically 15 15 15 15 15 15
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (15) (15) (15) (15) (15) (15)
Hematopoietic Cell Proliferation 1 (7%) 6 (40%)
Infiltration Cellular 1 (7%) 1 (7%)
Inflammation, Chronic Active 15 (100%) 14 (93%) 13 (87%) 13 (87%) 14 (93%) 8 (53%)
Myelodysplasia 2 (13%)
Pigmentation 12 (80%) 15 (100%) 12 (80%) 13 (87%) 14 (93%) 4 (27%)
Hepatocyte, Necrosis 4 (27%) 2 (13%) 1 (7%) 2 (13%) 1 (7%) 1 (7%)
Salivary Glands (1) (1)
Parotid Gland, Infiltration Cellular 1 (100%)
Tooth (1) (4) (3) (1) (3) (2)
Fibrosis 1 (50%)
Inflammation, Chronic Active 1 (100%)
Malformation 1 (33%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (15) (15) (15) (15) (15) (15)
Inflammation, Chronic Active 1 (7%)
Atrium, Thrombosis 1 (7%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Pituitary Gland (15) (15) (15) (15) (15) (15)
Pars Distalis, Angiectasis 1 (7%)
Pars Distalis, Cyst 1 (7%) 2 (13%) 1 (7%) 2 (13%) 2 (13%)
Thyroid Gland (15) (15) (15) (15) (15) (15)
Infiltration Cellular 1 (7%)
Inflammation, Chronic Active 2 (13%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Date: 07/12/02
Route: SKIN APPLICATION Time: 08:48:56
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (15) (15) (15) (15) (15) (15)
Cyst 1 (7%) 1 (7%) 1 (7%)
Inflammation, Chronic Active 1 (7%) 1 (7%)
Pigmentation 1 (7%) 1 (7%)
Uterus (15) (15) (15) (15) (15) (15)
Hydrometra 1 (7%) 1 (7%) 1 (7%) 1 (7%)
Inflammation, Chronic Active 1 (7%)
Cervix, Inflammation, Chronic Active 1 (7%)
Endometrium, Hyperplasia, Cystic 10 (67%) 11 (73%) 7 (47%) 8 (53%) 8 (53%) 9 (60%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node (11) (14) (13) (10) (13) (12)
Hematopoietic Cell Proliferation 2 (17%)
Hyperplasia 2 (17%)
Inguinal, Hematopoietic Cell Proliferation 1 (8%)
Inguinal, Hyperplasia 1 (8%)
Inguinal, Infiltration Cellular, Plasma Cell 2 (17%)
Inguinal, Myelodysplasia 2 (17%)
Mediastinal, Hematopoietic Cell Proliferation 5 (42%)
Mediastinal, Infiltration Cellular 1 (8%) 2 (17%)
Mediastinal, Infiltration Cellular, Plasma
Cell 2 (17%)
Lymph Node, Mandibular (15) (15) (15) (15) (15) (15)
Hematopoietic Cell Proliferation 1 (7%) 6 (40%)
Hyperplasia 1 (7%) 3 (20%) 2 (13%) 2 (13%) 3 (20%)
Hyperplasia, Plasma Cell 1 (7%) 1 (7%)
Infiltration Cellular 1 (7%) 1 (7%)
Infiltration Cellular, Plasma Cell 1 (7%) 2 (13%)
Inflammation, Chronic Active 1 (7%)
Myelodysplasia 1 (7%)
Lymph Node, Mesenteric (15) (14) (14) (15) (15) (15)
Hematopoietic Cell Proliferation 4 (27%)
Infiltration Cellular 2 (13%)
Spleen (15) (15) (15) (15) (15) (15)
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Date: 07/12/02
Route: SKIN APPLICATION Time: 08:48:56
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Atrophy 1 (7%) 3 (20%) 1 (7%) 2 (13%) 1 (7%)
Hematopoietic Cell Proliferation 7 (47%) 13 (87%) 9 (60%) 6 (40%) 8 (53%) 10 (67%)
Hyperplasia, Lymphoid 2 (13%) 2 (13%) 2 (13%)
Infiltration Cellular 1 (7%)
Myelodysplasia 2 (13%)
Thymus (15) (15) (15) (15) (15) (15)
Atrophy 1 (7%) 3 (20%) 2 (13%) 2 (13%) 3 (20%)
Thymocyte, Necrosis 2 (13%) 1 (7%) 1 (7%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (15) (15) (15) (15) (15) (15)
Epidermis, Skin, Site of Application,
Hyperplasia 1 (7%) 4 (27%) 15 (100%) 15 (100%)
Epidermis, Skin, Site of Application,
Hyperplasia, Focal 1 (7%) 1 (7%) 8 (53%)
Skin, Site of Application, Hyperkeratosis 1 (7%) 7 (47%) 14 (93%) 13 (87%)
Skin, Site of Application, Hyperplasia 1 (7%)
Skin, Site of Application, Inflammation,
Chronic Active 3 (20%) 14 (93%) 12 (80%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (15) (15) (15) (15) (15) (15)
Inflammation, Chronic Active 1 (7%)
Mediastinum, Infiltration Cellular 1 (7%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Date: 07/12/02
Route: SKIN APPLICATION Time: 08:48:56
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (15) (15) (15) (15) (15) (15)
Inflammation, Chronic Active 2 (13%) 3 (20%)
Mineralization 1 (7%)
Nephropathy 4 (27%) 1 (7%)
Renal Tubule, Cyst 1 (7%)
Renal Tubule, Regeneration 1 (7%) 2 (13%) 1 (7%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Date: 07/12/02
Route: SKIN APPLICATION Time: 08:48:56
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS MALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 15 15 15 15 15 15
Early Deaths
Natural Death 1 3 1 2 4
Survivors
Terminal Sacrifice 14 15 12 14 13 11
Animals Examined Microscopically 15 15 15 15 15 15
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (15) (15) (15) (15) (15) (15)
Basophilic Focus 1 (7%)
Hematopoietic Cell Proliferation 1 (7%) 1 (7%) 6 (40%)
Infarct 1 (7%)
Infiltration Cellular 5 (33%)
Inflammation, Acute 1 (7%)
Inflammation, Chronic Active 7 (47%) 10 (67%) 8 (53%) 8 (53%) 7 (47%) 8 (53%)
Mineralization 1 (7%)
Myelodysplasia 1 (7%)
Pigmentation 2 (13%)
Hepatocyte, Necrosis 2 (13%) 2 (13%) 2 (13%) 1 (7%) 1 (7%)
Mesentery (1) (1)
Fat, Necrosis 1 (100%) 1 (100%)
Salivary Glands (1) (1) (2)
Mandibular, Infiltration Cellular 1 (50%)
Stomach, Forestomach (15) (15) (15) (15) (15) (15)
Hyperkeratosis 1 (7%) 1 (7%) 3 (20%)
Inflammation, Chronic Active 1 (7%)
Epithelium, Hyperplasia 1 (7%)
Tooth (1) (3) (1) (2) (1) (1)
Inflammation, Chronic Active 1 (50%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (15) (15) (15) (15) (15) (15)
Atrium, Thrombosis 1 (7%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Date: 07/12/02
Route: SKIN APPLICATION Time: 08:48:56
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS MALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Adrenal Cortex (15) (15) (15) (15) (15) (15)
Hyperplasia 1 (7%)
Hypertrophy 7 (47%) 5 (33%) 9 (60%) 8 (53%) 5 (33%) 5 (33%)
Vacuolization Cytoplasmic 1 (7%)
Pituitary Gland (15) (15) (15) (14) (15) (15)
Pars Distalis, Cyst 2 (13%) 1 (7%) 1 (7%) 1 (7%) 1 (7%) 2 (13%)
Thyroid Gland (15) (15) (15) (15) (15) (15)
Inflammation, Chronic Active 1 (7%)
Follicle, Cyst 1 (7%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (15) (15) (15) (15) (15) (15)
Atrophy 1 (7%)
Inflammation, Chronic Active 2 (13%) 3 (20%)
Myelodysplasia 1 (7%)
Bilateral, Hypospermia 1 (7%)
Unilateral, Hypospermia 4 (27%) 3 (20%) 1 (7%) 1 (7%) 2 (13%)
Preputial Gland (1) (1)
Inflammation, Chronic Active 1 (100%)
Duct, Ectasia 1 (100%)
Testes (15) (15) (15) (15) (15) (15)
Cyst 2 (13%) 1 (7%) 1 (7%)
Bilateral, Germinal Epithelium, Degeneration 1 (7%)
Germinal Epithelium, Degeneration 1 (7%)
Unilateral, Germinal Epithelium, Degeneration 4 (27%) 3 (20%) 1 (7%) 1 (7%) 2 (13%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node (13) (13) (14) (15) (14) (14)
Hyperplasia 4 (29%)
Inflammation, Chronic Active 3 (21%)
Axillary, Infiltration Cellular 1 (7%)
Axillary, Infiltration Cellular, Plasma Cell 1 (7%)
Inguinal, Hyperplasia 1 (7%)
Inguinal, Inflammation, Chronic Active 1 (7%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Date: 07/12/02
Route: SKIN APPLICATION Time: 08:48:56
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS MALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Mediastinal, Hematopoietic Cell Proliferation 1 (7%)
Mediastinal, Hyperplasia 1 (7%)
Mediastinal, Infiltration Cellular 3 (21%)
Mediastinal, Infiltration Cellular, Plasma
Cell 3 (21%)
Mediastinal, Inflammation, Chronic Active 2 (14%)
Lymph Node, Mandibular (15) (14) (15) (15) (14) (13)
Hematopoietic Cell Proliferation 2 (15%)
Hyperplasia 1 (7%) 1 (8%)
Hyperplasia, Plasma Cell 1 (7%) 1 (7%)
Infiltration Cellular 4 (31%)
Infiltration Cellular, Plasma Cell 1 (8%)
Lymph Node, Mesenteric (15) (14) (14) (15) (15) (12)
Infiltration Cellular 1 (8%)
Spleen (15) (15) (15) (15) (15) (15)
Atrophy 1 (7%) 1 (7%) 4 (27%)
Depletion Cellular 1 (7%) 1 (7%)
Hematopoietic Cell Proliferation 1 (7%) 4 (27%) 1 (7%) 2 (13%) 6 (40%) 8 (53%)
Hyperplasia, Lymphoid 1 (7%) 1 (7%) 1 (7%) 1 (7%)
Thymus (15) (15) (14) (15) (15) (15)
Atrophy 1 (7%) 1 (7%) 2 (13%) 5 (33%)
Thymocyte, Necrosis 1 (7%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (15) (15) (15) (15) (15) (15)
Epidermis, Skin, Site of Application,
Hyperplasia 6 (40%) 14 (93%) 15 (100%)
Epidermis, Skin, Site of Application,
Hyperplasia, Focal 1 (7%) 1 (7%)
Skin, Site of Application, Hyperkeratosis 1 (7%) 15 (100%) 14 (93%) 12 (80%)
Skin, Site of Application, Hyperplasia 1 (7%)
Skin, Site of Application, Inflammation,
Chronic Active 1 (7%) 1 (7%) 9 (60%) 12 (80%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 88133-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: SUBCHRON 26-WEEK TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA) Date: 07/12/02
Route: SKIN APPLICATION Time: 08:48:56
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS MALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (15) (15) (15) (15) (15) (14)
Inflammation, Chronic Active 2 (13%) 2 (14%)
Thrombosis 1 (7%)
Interstitium, Hyperplasia 1 (7%)
Interstitium, Inflammation, Chronic Active 1 (7%)
Mediastinum, Infiltration Cellular 1 (7%)
Mediastinum, Inflammation, Chronic Active 1 (7%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (15) (15) (15) (15) (15) (15)
Infarct 1 (7%) 1 (7%)
Infiltration Cellular 1 (7%)
Infiltration Cellular, Mononuclear Cell 1 (7%) 1 (7%) 1 (7%)
Inflammation, Chronic Active 2 (13%) 1 (7%) 1 (7%) 5 (33%)
Mineralization 1 (7%)
Nephropathy 3 (20%) 6 (40%) 3 (20%)
Glomerulus, Renal Tubule, Dilatation 1 (7%)
Renal Tubule, Cyst 1 (7%) 1 (7%) 1 (7%)
Renal Tubule, Hyperplasia 1 (7%) 1 (7%) 1 (7%) 1 (7%)
Renal Tubule, Regeneration 2 (13%) 1 (7%) 5 (33%) 4 (27%) 4 (27%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------